TCGA-21-1080-01A-01R-0692-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.520
- E2F_TARGETS+0.460
- G2M_CHECKPOINT+0.450
- DNA_REPAIR+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.260
- OXIDATIVE_PHOSPHORYLATION+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- SPERMATOGENESIS+0.200
- NOTCH_SIGNALING+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- HEDGEHOG_SIGNALING-0.420
- ANGIOGENESIS-0.400
- INFLAMMATORY_RESPONSE-0.360
- UV_RESPONSE_DN-0.350
- HYPOXIA-0.340
- PANCREAS_BETA_CELLS-0.330
- COAGULATION-0.320
- TGF_BETA_SIGNALING-0.320
- KRAS_SIGNALING_UP-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15030859 | — | — | 0.917 |
| 2 | SRR3147738 | — | — | 0.905 |
| 3 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.898 |
| 4 | SRR650205 | — | — | 0.895 |
| 5 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.893 |
| 6 | MNG704 | — | — | 0.892 |
| 7 | SRR1313140 | — | E | 0.886 |
| 8 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.885 |
| 9 | 085e4228-8ed7-44d7-9ab5-8a096434b650 | — | — | 0.885 |
| 10 | SRR4195654 | — | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |